@article{3030754,
    title = "MUC5B promoter variant rs35705950 and rheumatoid arthritis associated
interstitial lung disease survival and progression",
    author = "Juge, Pierre-Antoine and Solomon, Joshua J. and van Moorsel, Coline H. and M. and Garofoli, Romain and Lee, Joyce S. and Louis-Sydney, Fabienne and and Rojas-Serrano, Jorge and Gonzalez-Perez, I, Montserrat and Mejia, Mayra and and Buendia-Roldan, Ivette and Falfan-Valencia, Ramces and and Ambrocio-Ortiz, Enrique and Manali, Effrosyni and Papiris, Spyros A. and and Karageorgas, Theofanis and Boumpas, Dimitrios and Antoniou, Katarina M. and and Sidiropoulos, Prodromos and Trachalaki, Athina and Van der Vis, and Joanne J. and Jamnitski, Anna and Grutters, Jan C. and Kannengiesser, and Caroline and Borie, Raphael and Kawano-Dourado, Leticia and and Wemeau-Stervinou, Lidwine and Flipo, Rene-Marc and Nunes, Hilario and and Uzunhan, Yurdagul and Valeyre, Dominique and Saidenberg-Kermanac'h, and Nathalie and Boissier, Marie-Christophe and Richez, Christophe and and Schaeverbeke, Thierry and Doyle, Tracy and Wolters, Paul J. and Debray, and Marie-Pierre and Boileau, Catherine and Porcher, Raphael and Schwartz, and David A. and Crestani, Bruno and Dieude, Philippe",
    journal = "Seminars in Arthritis and Rheumatism",
    year = "2021",
    volume = "51",
    number = "5",
    pages = "996-1004",
    publisher = "W B SAUNDERS CO-ELSEVIER INC",
    issn = "0049-0172",
    doi = "10.1016/j.semarthrit.2021.07.002",
    keywords = "Rheumatoid Arthritis; Interstitial Lung Disease; MUC5B; Genetics",
    abstract = "Background: The major risk factor for idiopathic pulmonary fibrosis
(IPF), MUC5B rs35705950, was found to be associated with rheumatoid
arthritis-associated interstitial lung disease (RA-ILD). Whilst the
MUC5B rs35705950 T risk allele has been associated with better survival
in IPF, its impact on RA-ILD prognosis remains to be determined. Our
objective was to explore the influence of MUC5B rs35705950 on survival
and progression in RA-ILD. Methods: Through an international
retrospective observational study, patients with RA-ILD were genotyped
for the MUC5B rs35705950 variant and consecutive pulmonary function
tests (PFTs) findings were collected. Longitudinal data up to a 10-year
follow-up were considered and analyzed using mixed regression models.
Proportional hazards and joint proportional hazards models were used to
analyze the association of baseline and longitudinal variables with lung
transplant-free survival. Significant progression of RA-ILD was defined
as at least an absolute or relative 10% decline of forced vital
capacity at 2 years from baseline. Results: Out of 321 registered
patients, 261 were included in the study: 139 women (53.3%), median age
at RA-ILD diagnosis 65 years (interquartile range [IQR] 57 to 71), 151
ever smokers (59.2%). Median follow-up was 3.5 years (IQR 1.3 to 6.6).
Mortality rate was 32% (95%CI 19 to 42) at 10 years. The MUC5B
rs35705950 variant did not impact lung transplant-free survival (HR for
the T risk allele carriers=1.26; 95%CI 0.61 to 2.62; P=0.53). Decline
in pulmonary function at 2 years was not influenced by MUC5B rs35705950
(OR=0.95; 95%CI 0.44 to 2.05; P=0.89), irrespective of the HRCT
pattern. Conclusion: In this study, the MUC5B rs35705950 promoter
variant did not influence transplant-free survival or decline in
pulmonary function in patients with RA-ILD. (c) 2021 Published by
Elsevier Inc."
}